This design ensures a preferential distribution of the antibodies to PD-1-expressing cells, namely, T cells and NK cells infiltrating the tumour and/or in tumour-draining lymph nodes (TDLNs) and avoids the liver toxicity caused by the systemic distribution of CD137 agonists. Here, TNFRSF9 is linked to neoplasm.